Document is current
Any future updates will be listed below
-
Authors
Wang, Yicheng
Ab Ghani, Nur Syatila
Dutta, Munmee
Adachi, Shungo
Katoh, Kaoru
Namihira, Masakazu
Mitsuyama, Toutai
Saito, Yutaka
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (22H03691, 19K20409)
Japan Agency for Medical Research and Development (JP19ak0101122)
Japan Association for Chemical Innovation (JACI) Prize
- License Information
-
More Information
Article History
Received: 6 October 2025
Accepted: 17 January 2026
First Online: 28 February 2026
Declarations
:
: The authors declare no competing interests.
: Human-induced pluripotent stem cells from a healthy individual (HPS0076) and from Rett syndrome patients (HPS3042, HPS3049 and HPS3084) used in this study were obtained from the RIKEN BRC through the National BioResource Project of the MEXT, Japan. The use of these cells was approved by the Institutional Human-Derived Sample Experimental Committee of National Institute of Advanced Industrial Science and Technology (AIST) (Approval No. 2023 − 0543). All procedures were conducted in compliance with institutional and national ethical guidelines.
